The Series B round, led by biotech entrepreneur Patrick Soon‑Shiong, will fund the startup’s effort to automate pharmaceutical production with clustered robots, aiming to lower costs and boost efficiency.
Multiply Labs announced a $75 million Series B financing round aimed at scaling its AI‑driven robotic platform for pharmaceutical manufacturing.
Funding round led by biotech veteran
The round was led by Patrick Soon‑Shiong, the biotech entrepreneur behind NantWorks, with participation from existing investors and strategic partners in the life‑science sector.
Technology focus: clustered robots and AI
Multiply Labs’ system combines multiple collaborative robots that work in coordinated clusters, guided by machine‑learning models that optimize process parameters in real time.
The AI engine continuously analyzes sensor data from each robot, adjusting temperature, mixing speed, and material handling to maintain tight tolerances required for drug production.
Strategic goals for pharmaceutical manufacturers
The funding will be used to pilot the technology in large‑scale API (active pharmaceutical ingredient) facilities, with the aim of reducing batch‑to‑batch variability and cutting operational costs.
Multiply Labs plans to integrate its platform with existing manufacturing execution systems, offering a modular upgrade path for companies that want to automate without a complete plant overhaul.
- Accelerated batch cycles through predictive process control
- Lowered labor expenses by replacing manual handling with coordinated robots
- Improved compliance via continuous monitoring and automated documentation
Industry reaction
Analysts note that the infusion of AI into robotic manufacturing could address long‑standing bottlenecks in drug supply chains, especially for high‑volume generic products.
“Automation that learns on the fly is a game‑changer for pharma,” said a senior analyst at a leading market research firm.
Multiply Labs expects its first commercial deployments to begin in late 2027, targeting both established pharma firms and emerging biotech manufacturers.